Veritas In Silico (130A) · TargetAdvanced
Creation of the Second In-House Pipeline in Fiscal 2026
First written in FY2025. 3 of 5 entries say "Advanced", first in 2026-05-11. Latest entry: FY2026-H1.
5entries
1years
3from disclosures
How it moved
Same theme, other companies
Continuous creation of new drugs and pipeline expansionA theme 17 companies write about · 0 as a headwind · 23 as a tailwind
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.Full recordFilings, disclosures and news, newest first
- FY2026-H1AdvancedAnnual report
「Research toward the creation of nucleic acid drugs with Mitsubishi Gas Chemical Company, Inc. (Pipeline 2) is also progressing smoothly, and in July 2026 we filed a composition-of-matter patent application for a drug candidate obtained through the research.」
Pipeline 2, which was to be created in FY2026, advanced to the stage of obtaining a drug-candidate substance through research and filing a substance patent application in July 2026. - FY2025First statedAnnual report
「Pipeline 2 will be created in FY2026.」
The medium-term management plan sets a target of creating the second in-house pipeline in FY2026 as part of the goal of establishing the company as a specialty pharma by 2030.